<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cvrx, Inc. — News on 6ix</title>
<link>https://6ix.com/company/cvrx-inc</link>
<description>Latest news and press releases for Cvrx, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 20 May 2026 20:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cvrx-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355b0e78dffbe2df0ebbca.webp</url>
<title>Cvrx, Inc.</title>
<link>https://6ix.com/company/cvrx-inc</link>
</image>
<item>
<title>CVRx to Present at the William Blair 46th Annual Growth Stock Conference</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-to-present-at-the-william-blair-46th-annual-growth-stock-conference</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-to-present-at-the-william-blair-46th-annual-growth-stock-conference</guid>
<pubDate>Wed, 20 May 2026 20:30:00 GMT</pubDate>
<description>MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026. The Company's presentation will begin at 10:40 a.m. (CT). A live webcast of the event can b</description>
</item>
<item>
<title>CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-announces-humana-medicare-advantage-coverage-policy-for-barostim-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-announces-humana-medicare-advantage-coverage-policy-for-barostim-therapy</guid>
<pubDate>Thu, 14 May 2026 04:00:00 GMT</pubDate>
<description>MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing,</description>
</item>
<item>
<title>CVRx Reports First Quarter 2026 Financial and Operating Results</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-reports-first-quarter-2026-financial-and-operating-results</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-reports-first-quarter-2026-financial-and-operating-results</guid>
<pubDate>Mon, 11 May 2026 20:05:00 GMT</pubDate>
<description>MINNEAPOLIS, May 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2026. Recent Highlights Total revenue for the first quarter of 2026 was $14.8 million, an increase of approximately 20% over the prior year quarterU.S. revenue fo</description>
</item>
<item>
<title>CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-announces-first-patient-enrollment-in-benefit-hf-a-landmark-heart-failure-trial-evaluating-barostim-in-significantly-expanded-population</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-announces-first-patient-enrollment-in-benefit-hf-a-landmark-heart-failure-trial-evaluating-barostim-in-significantly-expanded-population</guid>
<pubDate>Mon, 04 May 2026 20:30:00 GMT</pubDate>
<description>MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced the enrollment of the first patient in the landmark BENEFIT-HF trial at North Central Heart - a division of the Avera Heart Hospital, in Sioux Falls, S.D. by Dr. Orvar Jonsson. BENEFIT-HF is expected to be one of the largest therapeutic cardiac devi</description>
</item>
<item>
<title>CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-to-report-first-quarter-2026-financial-and-operating-results-and-host-conference-call-on-may-11-2026</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-to-report-first-quarter-2026-financial-and-operating-results-and-host-conference-call-on-may-11-2026</guid>
<pubDate>Mon, 27 Apr 2026 20:30:00 GMT</pubDate>
<description>MINNEAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release first quarter 2026 financial and operating results after market close on Monday, May 11, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.</description>
</item>
<item>
<title>CVRx Announces Nomination of Michael Dale for Election to the Board of Directors</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-announces-nomination-of-michael-dale-for-election-to-the-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-announces-nomination-of-michael-dale-for-election-to-the-board-of-directors</guid>
<pubDate>Mon, 20 Apr 2026 20:30:00 GMT</pubDate>
<description>MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the nomination of Michael Dale to serve on its Board of Directors. Mr. Dale will stand for election at the annual meeting of stockholders scheduled for June 1, 2026. "Michael has achieved an outstanding record of commercial success in the medical</description>
</item>
<item>
<title>CVRx Reports Preliminary First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-reports-preliminary-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-reports-preliminary-first-quarter-2026-financial-results</guid>
<pubDate>Mon, 13 Apr 2026 12:00:00 GMT</pubDate>
<description>Delivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025Early data in 2026 shows an increase in the 30-day approval rate for Medicare Advantage prior authorizations managed by our market access teamFirst site activated in BENEFIT-HF clinical trial MINNEAPOLIS, April 13, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on de</description>
</item>
<item>
<title>CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-announces-late-breaking-data-and-scientific-presentations-highlighting-barostim-outcomes-at-the-tht-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-announces-late-breaking-data-and-scientific-presentations-highlighting-barostim-outcomes-at-the-tht-2026-annual-meeting</guid>
<pubDate>Mon, 02 Mar 2026 13:30:00 GMT</pubDate>
<description>MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations reviewing the science and outcomes of Barostim therapy at the Technology and Heart Failure Therapeutics 2026 (THT) meeting. THT, the annual conference organized by the Cardiovascular Research Foundation® (C</description>
</item>
<item>
<title>CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-reports-fourth-quarter-full-210500150</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-reports-fourth-quarter-full-210500150</guid>
<pubDate>Thu, 12 Feb 2026 21:05:00 GMT</pubDate>
<description>MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025. Recent Highlights Total revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarterU.S. revenue for</description>
</item>
<item>
<title>CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-report-fourth-quarter-2025-211000275</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-report-fourth-quarter-2025-211000275</guid>
<pubDate>Thu, 29 Jan 2026 21:10:00 GMT</pubDate>
<description>MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2025 financial and operating results after market close on Thursday, Feb. 12, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same d</description>
</item>
<item>
<title>CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-announces-initiation-benefit-hf-210500264</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-announces-initiation-benefit-hf-210500264</guid>
<pubDate>Thu, 22 Jan 2026 21:05:00 GMT</pubDate>
<description>Study is Expected to Be One of the Largest Therapeutic Cardiac Device Trials in Heart Failure Ever Performed, and is Supported by CMS Category B IDE CoverageMINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced initiation of the BENEFIT-HF clinical trial, a landmark randomized study supported by CMS C</description>
</item>
<item>
<title>CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-reports-preliminary-fourth-quarter-130000286</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-reports-preliminary-fourth-quarter-130000286</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5%Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11%Fiscal 2026 revenue expected to be between $63 million and $67 million, representing growth of 11% to 18%Category I CPT codes and the related favorable physician fee payment levels took effect on Jan. 1, 2026FDA approved the BENEFIT-HF trial design in November and the Company has since applied to CMS</description>
</item>
<item>
<title>CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-announces-implementation-category-cpt-133000521</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-announces-implementation-category-cpt-133000521</guid>
<pubDate>Tue, 06 Jan 2026 13:30:00 GMT</pubDate>
<description>MINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, confirmed today that Category I Current Procedural Terminology (CPT) codes for baroreflex activation therapy using its Barostim device replaced the Category III codes as of Jan. 1, 2026. In the U.S. healthcare system, Category I CPT codes</description>
</item>
<item>
<title>CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-present-44th-annual-j-133000868</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-present-44th-annual-j-133000868</guid>
<pubDate>Mon, 22 Dec 2025 13:30:00 GMT</pubDate>
<description>MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The Company's presentation will begin at 3:45 p.m. (PT). A live webcast of the event</description>
</item>
<item>
<title>CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-participate-piper-sandler-37th-133000176</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-participate-piper-sandler-37th-133000176</guid>
<pubDate>Wed, 19 Nov 2025 13:30:00 GMT</pubDate>
<description>MINNEAPOLIS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, Dec. 3, 2025. The fireside chat is scheduled at 2:00 p.m. (ET) the same day via webcast. A l</description>
</item>
<item>
<title>CVRx Reports Third Quarter 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-reports-third-quarter-2025-210500587</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-reports-third-quarter-2025-210500587</guid>
<pubDate>Wed, 05 Nov 2025 21:05:00 GMT</pubDate>
<description>MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2025. Recent Highlights Total revenue for the third quarter 2025 was $14.7 million, an increase of 10% over the prior year quarterU.S. revenue for the third quar</description>
</item>
<item>
<title>CVRx to Present at the Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-present-jefferies-global-healthcare-133000085</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-present-jefferies-global-healthcare-133000085</guid>
<pubDate>Tue, 04 Nov 2025 13:30:00 GMT</pubDate>
<description>MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025. The Company is scheduled to present at 8:00 a.m. (GMT) / 4:00 a.m. (ET) the same day via webcast. A l</description>
</item>
<item>
<title>CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-report-third-quarter-2025-203000726</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-report-third-quarter-2025-203000726</guid>
<pubDate>Wed, 22 Oct 2025 20:30:00 GMT</pubDate>
<description>MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2025 financial and operating results after market close on Wednesday, Nov. 5, 2025. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same da</description>
</item>
<item>
<title>CVRx Reports Second Quarter 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-reports-second-quarter-2025-200500877</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-reports-second-quarter-2025-200500877</guid>
<pubDate>Mon, 04 Aug 2025 20:05:00 GMT</pubDate>
<description>MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2025. Recent Highlights Total revenue for the second quarter 2025 was $13.6 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) reven</description>
</item>
<item>
<title>CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference</title>
<link>https://6ix.com/company/cvrx-inc/news/cvrx-present-canaccord-genuity-45th-123000526</link>
<guid isPermaLink="true">https://6ix.com/company/cvrx-inc/news/cvrx-present-canaccord-genuity-45th-123000526</guid>
<pubDate>Tue, 29 Jul 2025 12:30:00 GMT</pubDate>
<description>MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast. A live audio we</description>
</item>
</channel>
</rss>